About this trial
The goal of this clinical trial is to investigate the effect of theta burst stimulation for depression and serum brain-derived neurotrophic factor (BDNF) in individuals with major depression. The main question it aims to answer is whether 10 sessions of theta burst stimulation can influence the serum level of BDNF.
Participants will be randomized into active group and sham group. Researchers will compare the level of BDNF in these groups.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age between 20 and 65 years;
fulfilling the Diagnostic and Statistical Manual version 5 (DSM-5) criteria of Major depressive disorder assessed by the Structured Clinical Interview
Disqualifiers
Inability to provide informed consent or comprehend the study procedure;
A major psychiatric illness including schizophrenia spectrum disorder, bipolar spectrum disorder, and major depressive disorder with psychotic features.
A current DSM-5 diagnosis of substance use disorder except nicotine use disorder or the use of one to two low-potency benzodiazepine tablets for sleep impairment;
Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxic medications, or with cochlear implants.
Trial design
Parallel
Treatments tested in this trial
Theta Burst Stimulation
DeviceTheta Burst Stimulation
Treatment groups
Trial outcomes
Primary outcomes
Change in depression severity
Measured by Montgomery-Asberg Depression Rating Scale (MADRS)
Secondary outcomes
Change in brain-derived neurotrophic factor (BDNF)
Serum level of BDNF
Sponsors and contacts
Click on the lead sponsor to view all of their trials.